Vimta Labs Limited reported Q2 FY '27 total income of INR1,149 million, up 9.9% year-on-year, EBITDA of INR408 million and a 35.5% margin. Biologics began generating revenue, while CRADS and clinical research are expected to improve in Q3 and Q4.

5 source passages

Total income for Q2 FY '27 stood at INR1,149 million as compared to INR1,045 million in Q2 FY '26, up by 9.9% year-on-year. EBITDA stood at INR408 million in Q2 FY '27 as compared to INR369 million in Q2 FY '26, up by 10.5% year-on-year. EBITDA margin for the quarter stood at 35.5%. A key milestone during Q2 was the commencement of revenue generation from our biologics services. Looking ahead, we expect improvement in CRADS, which is Contract Research and Development Services for large molecules and clinical research during Q3 and Q4. I would request Ms. Harita Vasireddi, Managing Director of Vimta Labs Limited to provide you with the update for the quarter and half year ended 30th September '26. Open the document at this passage

Jul 20

Earnings call

Q1 2027 earnings call AI summary on its way

May 6

Earnings call

Q4 2026 earnings call AI summary on its way

Jan 28

Earnings call

Q3 2026 earnings call AI summary on its way

Showing 1–4 of 4 documents